Management of polyuria in autosomal dominant polycystic kidney disease after treatment with tolvaptan: an educational approach-Reference-Cited by-同舟云学术

Management of polyuria in autosomal dominant polycystic kidney disease after treatment with tolvaptan: an educational approach

Published:2020-01-02 Issue:1 Volume:5 Page:26-29
ISSN:2397-9534
Container-title:Journal of Kidney Care
language:en
Short-container-title:Journal of Kidney Care

Author:

Brioni Elena¹,Magnaghi Cristiano²,Silingardi Marco³

Affiliation:

1. Clinical Research Nurse and Nursing Researcher, Genomics of Renal Disease and Hypertension Unit, Ospedale San Raffaele, Milan, Italy, and Società Infermieri Area Nefrologica

2. Dialysis and Research Nurse, Nephrology and Dialysis Unit, San Raffaele Hospital, Milan, Italy and Società Infermieri Area Nefrologica

3. Matron, Stroke Unit, Salford Royal Hospital, Manchester, and Società Infermieri Area Nefrologica

Abstract

Tolvaptan is the first drug to be approved for delaying the progression of autosomal dominant polysystic disease in adults with stage 1–3 chronic kidney disease. Its mode of action, however, results in polyuria. An adequate educational programme is required to help individuals maintain adherence to the medication and deal with the side-effects.

Publisher

Mark Allen Group

Link

http://www.magonlinelibrary.com/doi/pdf/10.12968/jokc.2020.5.1.26

Reference23 articles.

1. Addressing the Challenges of Adherence

2. Evaluation of Polyuria: The Roles of Solute Loading and Water Diuresis

3. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease

4. Approaches to Testing New Treatments in Autosomal Dominant Polycystic Kidney Disease: Insights from the CRISP and HALT-PKD Studies

5. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference